[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

5 Stocks Our Top Technical Strategist is Tracking Now

Well, if you decided to sell in May and go away, you might have some FOMO after week one.

The SPDR S&P 500 ETF (SPY) is already up more than 2% so far on the month, compared to its average May return of 0.58% since 2010. Looking back at very recent history, SPY has far outpaced its typical May performance by surging 6% in 2025 and 5% in 2024, so we may yet have some upside left to go here before it’s all said and done.

Fundamentals

See More
  • Market Capitalization, $K 14,166,741
  • Shares Outstanding, K 62,743
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 224 M
  • EBITDA $ 921 M
  • 60-Month Beta 0.27
  • Price/Sales 3.34
  • Price/Cash Flow 13.96
  • Price/Book 3.14

Options Overview Details

View History
  • Implied Volatility 32.45% (+1.11%)
  • Historical Volatility 33.91%
  • IV Percentile 12%
  • IV Rank 15.14%
  • IV High 69.53% on 08/05/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 5) 3.40 (1.51%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 151
  • Volume Avg (30-Day) 346
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 9,974
  • Open Int (30-Day) 8,509
  • Expected Range 222.39 to 229.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $5.16
  • Number of Estimates 4
  • High Estimate $5.63
  • Low Estimate $4.68
  • Prior Year $-9.07
  • Growth Rate Est. (year over year) +156.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.32 +17.40%
on 04/10/26
230.40 -2.00%
on 05/06/26
+29.86 (+15.24%)
since 04/08/26
3-Month
161.38 +39.91%
on 02/11/26
230.40 -2.00%
on 05/06/26
+60.29 (+36.43%)
since 02/06/26
52-Week
97.56 +131.44%
on 05/09/25
230.40 -2.00%
on 05/06/26
+127.38 (+129.44%)
since 05/08/25

Most Recent Stories

More News
5 Stocks Our Top Technical Strategist is Tracking Now

From the pullback in refining stock PSX to the breakout in AI pick Corning, here’s what John Rowland is watching ahead of Friday’s livestream.

NVDA : 215.20 (+1.75%)
FSLR : 219.95 (+2.51%)
GLW : 186.94 (+2.49%)
PSX : 171.56 (+1.93%)
JAZZ : 225.79 (-0.52%)
SPY : 737.62 (+0.83%)
JOBY : 10.87 (+8.59%)
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

JAZZ : 225.79 (-0.52%)
JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals

JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals

JAZZ : 225.79 (-0.52%)
Jazz: Q1 Earnings Snapshot

Jazz: Q1 Earnings Snapshot

JAZZ : 225.79 (-0.52%)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales

JAZZ : 225.79 (-0.52%)
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) –

JAZZ : 225.79 (-0.52%)
Jazz Pharmaceuticals' Oncology Pipeline Momentum Meets the Reality of Legacy Franchise Erosion

Barchart Research What to Expect from JAZZ Earnings JAZZ Generated May 4, 2026 Current Price $208.06 EPS Estimate $$3.82 Consensus Rating Strong Buy Average Move 5.67% Jazz Pharmaceuticals' Oncology Pipeline...

JAZZ : 225.79 (-0.52%)
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For

Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For

JAZZ : 225.79 (-0.52%)
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026

JAZZ : 225.79 (-0.52%)
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

JAZZ : 225.79 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 236.07
2nd Resistance Point 233.04
1st Resistance Point 229.41
Last Price 225.79
1st Support Level 222.75
2nd Support Level 219.72
3rd Support Level 216.09

See More

52-Week High 230.40
Last Price 225.79
Fibonacci 61.8% 179.66
Fibonacci 50% 163.98
Fibonacci 38.2% 148.30
52-Week Low 97.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.